SyB V-1901 (Generic Name: Brincidofovir, BCV) is a lipid conjugate of cidofovir (CDV). CDV is an antiviral drug already approved and marketed in the United States and the European Union. As BCV exhibits not only higher anti-viral activity, but also a superior safety profile in comparison with CDV, BCV is expected to be an effective treatment against a wide spectrum of infectious diseases caused by DNA viruses, including herpes viruses (including CMV), adenovirus, BK virus, papilloma virus, and smallpox virus.
Under the terms of a license agreement with Chimerix Inc. (Headquarters: Durham, NC) dated September 30, 2019, SymBio obtained the exclusive worldwide rights to develop, manufacture, and commercialize BCV in all human indications, excluding the prevention and treatment of orthopox infections (which includes smallpox and monkeypox). Based on existing strong data, SymBio will first target adenovirus infection in immunocompromised patients including allogeneic hematopoietic stem cell transplantation to address the critically underserved therapeutic areas.